{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:08:20Z","timestamp":1780056500159,"version":"3.54.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.disamonth.2026.102150","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:29:27Z","timestamp":1780054167000},"page":"102150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review"],"prefix":"10.1016","author":[{"given":"Rushin S","family":"Parekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pugazhendi","family":"Inban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dastan","family":"Kudaiarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2026.102150_bib0001","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review","volume":"16","author":"Hamed","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102150_bib0002","unstructured":"Collins L., Costello R.A. Glucagon-Like Peptide-1 Receptor Agonists 2024."},{"key":"10.1016\/j.disamonth.2026.102150_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0004","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms27041886","article-title":"The multifaceted nature of GLP-1: molecular mechanisms and signaling pathways in metabolic and neurodegenerative diseases","volume":"27","author":"Kowalska","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.disamonth.2026.102150_bib0005","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-025-67701-9","article-title":"Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases","volume":"17","author":"Kong","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.disamonth.2026.102150_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.disamonth.2026.102150_bib0007","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/j.jtha.2025.06.020","article-title":"Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Chiang","year":"2025","journal-title":"J Thrombos Haemostasis"},{"key":"10.1016\/j.disamonth.2026.102150_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103389","article-title":"Global trends in mortality related to pulmonary embolism: an epidemiological analysis of data from the World Health Organization mortality database from 2001 to 2023","volume":"86","author":"Hagiya","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102150_bib0009","article-title":"Epidemiology of venous thromboembolism: implications for clinical practice","volume":"135","author":"Marschang","year":"2025","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0010","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke statistics - 2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.disamonth.2026.102150_bib0011","first-page":"250","article-title":"Venous thromboembolism and obesity: moving toward a better understanding of the population-attributable risk","volume":"124","author":"Martin","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.disamonth.2026.102150_bib0012","article-title":"The interplay between obesity and venous thromboembolism: from molecular aspects to clinical issue","volume":"26","author":"Cannataro","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102150_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0043-1772212","article-title":"The risk of incident venous thromboembolism attributed to overweight and obesity: the Troms\u00f8 study","volume":"124","author":"Frischmuth","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.disamonth.2026.102150_bib0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4236\/ojpm.2012.24069","article-title":"The effects of obesity on venous thromboembolism: a review","volume":"2012","author":"Yang","year":"2012","journal-title":"Open J Prev Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0016","article-title":"The associations between obesity and deep vein thrombosis in patients with cardiovascular disease: a narrative review","volume":"16","author":"Sanchez","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102150_bib0017","doi-asserted-by":"crossref","first-page":"436","DOI":"10.31083\/j.rcm2512436","article-title":"Diabetes Mellitus and cardiovascular Disease: exploring epidemiology, pathophysiology, and treatment strategies","volume":"25","author":"Siam","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70167","article-title":"Intersecting molecular pathways in cardiovascular disease and diabetes mellitus: emerging roles of inflammation and therapeutics","volume":"42","author":"Anagnostopoulou","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.disamonth.2026.102150_bib0019","article-title":"Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOH.0b013e3283634443","article-title":"Mechanisms of thrombosis in obesity","volume":"20","author":"Blokhin","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15386\/mpr-1372","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu","year":"2020","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.disamonth.2026.102150_bib0022","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.disamonth.2026.102150_bib0023","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.disamonth.2026.102150_bib0024","unstructured":"GLP-1 drugs effective for weight loss, but more independent studies needed | Cochrane n.d. https:\/\/www.cochrane.org\/about-us\/news\/glp-1-drugs-effective-weight-loss-more-independent-studies-needed (accessed April 28, 2026)."},{"key":"10.1016\/j.disamonth.2026.102150_bib0025","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102150_bib0026","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini","year":"2023","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.disamonth.2026.102150_bib0027","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10557-025-07670-9","article-title":"Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications","volume":"40","author":"Zhang","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.disamonth.2026.102150_bib0028","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.hlc.2021.07.024","article-title":"Glucagon-like peptide-1 receptor agonists and brain vascular function","volume":"30","author":"Begic","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.disamonth.2026.102150_bib0029","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.disamonth.2026.102150_bib0030","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.3390\/ijms26146777","article-title":"Molecular insights into the potential cardiometabolic effects of GLP-1 receptor analogs and DPP-4 inhibitors","volume":"26","author":"Kr\u00f3l","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102150_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0032","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0033","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ehjcvp\/pvaf037","article-title":"Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"11","author":"Kalayci","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.disamonth.2026.102150_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039446","article-title":"Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.disamonth.2026.102150_bib0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/biomedicines14040743","article-title":"Integrating GLP-1 Receptor agonists into modern stroke prevention: evidence, mechanisms, and clinical consideration\u2014a narrative review","volume":"14","author":"Khan","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.disamonth.2026.102150_bib0036","doi-asserted-by":"crossref","first-page":"28","DOI":"10.59931\/rcp.25.0004","article-title":"Association between cancer and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review of retrospective cohort studies","volume":"3","author":"Park","year":"2025","journal-title":"Researh in Clinical Pharmacy"},{"key":"10.1016\/j.disamonth.2026.102150_bib0037","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"Lancet Reg Health - Europe"},{"key":"10.1016\/j.disamonth.2026.102150_bib0038","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2025.2562077","article-title":"Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists","volume":"18","author":"Chiang","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.disamonth.2026.102150_bib0040","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1016\/j.vaccine.2023.11.005","article-title":"Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine","volume":"41","author":"Grabenstein","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.disamonth.2026.102150_bib0041","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102150_bib0042","doi-asserted-by":"crossref","DOI":"10.1007\/s00266-026-05805-3","article-title":"Preoperative GLP-1 receptor agonists and thromboinflammatory markers in patients undergoing abdominoplasty: a prospective monocentric study","author":"Bruno","year":"2026","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.disamonth.2026.102150_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EC-16-0113","article-title":"Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential","volume":"6","author":"Nylander","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.disamonth.2026.102150_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02706-8","article-title":"Interleukin-1\u03b2 in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes","volume":"24","author":"Simeone","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0045","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0046","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0047","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0048","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0049","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.disamonth.2026.102150_bib0051","doi-asserted-by":"crossref","unstructured":"Dai H., Lee Y.A., Natalie A., Jackson W., Pham A., Levine J., et al. GLP-1 receptor agonists and cardiovascular events in adults with obesity and autoimmune disease: a target trial emulation. MedRxiv 2025:2025.11.10.25339912. https:\/\/doi.org\/10.1101\/2025.11.10.25339912.","DOI":"10.1101\/2025.11.10.25339912"},{"key":"10.1016\/j.disamonth.2026.102150_bib0052","doi-asserted-by":"crossref","first-page":"215","DOI":"10.34172\/jcvtr.025.33793","article-title":"The cardiovascular safety of GLP-1 receptor agonists: from glucose control to cardiometabolic protection","volume":"17","author":"Ghaffari","year":"2025","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.disamonth.2026.102150_bib0053","first-page":"1","article-title":"Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes","author":"Xu","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0054","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data","volume":"117","author":"Wang","year":"2025","journal-title":"JNCI"},{"key":"10.1016\/j.disamonth.2026.102150_bib0055","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.tem.2025.03.015","article-title":"Promising results but caution needed in GLP-1RA large scale epidemiology","volume":"36","author":"Deo","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70082","article-title":"Efficacy of GLP-1 receptor agonist-based therapies on cardiovascular events and cardiometabolic parameters in obese individuals without diabetes: a meta-analysis of randomized controlled trials","volume":"17","author":"Yin","year":"2025","journal-title":"J Diabetes"},{"key":"10.1016\/j.disamonth.2026.102150_bib0057","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1453297","article-title":"Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis","volume":"11","author":"Kelkar","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0059","unstructured":"GLP-1 agonists 2026: efficacy, safety, uses review n.d. https:\/\/www.nationwidepeptides.com\/peptide\/glp-1-agonists-2026-review-2\/ (accessed April 28, 2026)."},{"key":"10.1016\/j.disamonth.2026.102150_bib0060","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000047994","article-title":"GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Ahmad","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.disamonth.2026.102150_bib0061","doi-asserted-by":"crossref","first-page":"285","DOI":"10.14740\/jocmr6231","article-title":"Comparative efficacy of tirzepatide vs. Semaglutide in reducing body weight in humans: a systematic review and meta-analysis of clinical trials and real-world data","volume":"17","author":"Aamir A","year":"2025","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.disamonth.2026.102150_bib0062","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1007\/s12325-025-03340-2","article-title":"Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE)","volume":"42","author":"Ng","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.disamonth.2026.102150_bib0063","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized Controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.disamonth.2026.102150_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103464","article-title":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","volume":"88","author":"Chu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102150_bib0065","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.82","article-title":"Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: a retrospective cohort study","volume":"2","author":"Petroni","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0066","article-title":"Weight loss that lasts: reviewing the long-term impact of GLP-1 receptor agonists","volume":"17","author":"Shah","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102150_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039446","article-title":"Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.disamonth.2026.102150_bib0068","article-title":"Deep venous thrombosis within two weeks of initiating oral semaglutide (Rybelsus): a case report","volume":"18","author":"Alsermani","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102150_bib0069","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2026.102150_bib0070","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1186\/s40001-025-03241-8","article-title":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","volume":"30","author":"Yao","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.disamonth.2026.102150_bib0071","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0072","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.13888","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials","volume":"22","author":"Mannucci","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0073","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0074","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/s12872-025-05278-3","article-title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Sadraei","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.disamonth.2026.102150_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1731127","article-title":"Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"12","author":"Tan","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0076","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/bloodadvances.2025015871","article-title":"Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation","volume":"9","author":"Chiang","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.disamonth.2026.102150_bib0077","article-title":"Real-world evidence and observational studies: methodological challenges in clinical research","volume":"56","author":"Zoccali","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.disamonth.2026.102150_bib0078","doi-asserted-by":"crossref","first-page":"107","DOI":"10.18773\/austprescr.2025.024","article-title":"Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication)","volume":"48","year":"2025","journal-title":"Aust Prescr"},{"key":"10.1016\/j.disamonth.2026.102150_bib0079","article-title":"Barriers and facilitators to the implementation of guidelines for venous thromboembolism prevention and management: a mixed-methods systematic review","volume":"8","author":"Han","year":"2024","journal-title":"Int J Nurs Stud Adv"},{"key":"10.1016\/j.disamonth.2026.102150_bib0080","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.3390\/jcm14238531","article-title":"Preferences among expert physicians in areas of uncertainty in venous thromboembolism management: results from a multiple-choice questionnaire","volume":"14","author":"Di Minno","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0081","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/bloodadvances.2025016052","article-title":"Weighing the evidence on GLP1s and venous thromboembolism","volume":"9","author":"Houghton","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.disamonth.2026.102150_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0083","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0084","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0085","doi-asserted-by":"crossref","DOI":"10.2147\/DMSO.S585436","article-title":"A clinical comprehensive evaluation of long-acting GLP-1 receptor agonists in type 2 diabetes management","volume":"19","author":"Chen","year":"2026","journal-title":"Diabetes, Metab Syndr Obes"},{"key":"10.1016\/j.disamonth.2026.102150_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102150_bib0087","doi-asserted-by":"crossref","first-page":"JC11","DOI":"10.7326\/ANNALS-25-05161-JC","article-title":"GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs. placebo","volume":"179","author":"Anderson","year":"2026","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0088","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.disamonth.2026.102150_bib0089","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102150_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.733","article-title":"GLP-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis","volume":"44","author":"Ailawadi","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0091","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.disamonth.2026.102150_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70113","article-title":"Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1736380","article-title":"Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies","volume":"17","author":"Wali","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0094","article-title":"Non-arteritic anterior ischemic optic neuropathy associated with the use of phosphodiesterase type 5 inhibitors: a literature review","volume":"14","author":"Hor","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102150_bib0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.disamonth.2026.102150_bib0096","doi-asserted-by":"crossref","DOI":"10.7570\/jomes25081","article-title":"Evaluating the safety profile of glucagon-like peptide-1 receptor agonists: adverse events and clinical recommendations","author":"Kim","year":"2026","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.disamonth.2026.102150_bib0097","article-title":"Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102150_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"10","key":"10.1016\/j.disamonth.2026.102150_bib0099","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes"},{"key":"10.1016\/j.disamonth.2026.102150_bib0100","first-page":"1987","article-title":"Gastrointestinal adverse effects of anti-obesity medications in non-diabetic adults: a systematic review","volume":"61","author":"Takrori","year":"2025","journal-title":"Medicina (Lithuania)"},{"issue":"10","key":"10.1016\/j.disamonth.2026.102150_bib0101","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes"},{"key":"10.1016\/j.disamonth.2026.102150_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70134","article-title":"Efficacy and safety of Orforglipron in obese adults with or without diabetes: a systematic review and meta-analysis","volume":"8","author":"Pandey","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.disamonth.2026.102150_bib0103","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","article-title":"Benefit-risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons","volume":"15","author":"Cedirian","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.disamonth.2026.102150_bib0104","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292600088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001150292600088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:29:39Z","timestamp":1780054179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001150292600088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":104,"alternative-id":["S001150292600088X"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102150","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102150"}}